Synmosa Biopharma Corporation (TPEX: 4114)

Market Cap	16.11B
Revenue (ttm)	5.19B
Net Income (ttm)	689.09M
Shares Out	424.62M
EPS (ttm)	1.63
PE Ratio	23.24
Forward PE	17.73
Dividend	0.55 (1.45%)
Ex-Dividend Date	Aug 9, 2024

Volume	880,914
Open	38.05
Previous Close	37.65
Day's Range	37.75 - 38.30
52-Week Range	32.23 - 39.67
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. It also offers contract manufacturing services. In addi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2023, Synmosa Biopharma's revenue was 5.14 billion, an increase of 17.19% compared to the previous year's 4.39 billion. Earnings were 594.83 million, a decrease of -25.56%.